What is the difference between Section 361 and Section 362 HCT/Ps under 21 CFR Part 1271?

Section 361 HCT/Ps are regulated solely to prevent disease transmission and do not require pre-market approval, provided they meet strict criteria for minimal manipulation and homologous use. Section 362 products fail one or more of these criteria and are regulated as biologics, drugs, or devices requiring FDA pre-market approval or an IND.

Does a medical practice using HCT/Ps need to register directly with the FDA?

Generally, end-user clinical practices that only receive, store, and apply compliant HCT/Ps for patient care within their facility do not need to register with the FDA. However, the manufacturers, processors, and distributors supplying those products must maintain active FDA registration.

How long must a medical practice retain tissue product tracking records?

FDA 21 CFR Part 1271 regulations require tissue tracking records—including donor identification numbers, lot numbers, expiration dates, and patient association logs—to be retained for at least 10 years after administration or expiration.

What documents should a practice request from a tissue distributor before purchasing?

A practice should request the supplier's active FDA Form 3356 registration, a Certificate of Analysis (CoA) for donor eligibility testing, handling and storage specifications, and product validation documentation confirming minimal manipulation and intended homologous use.

FDA 21 CFR Part 1271 Tissue Procurement Compliance Guide

FDA 21 CFR Part 1271 establishes the regulatory framework governing human cells, tissues, and cellular and tissue-based products (HCT/Ps). To maintain legal and operational compliance, medical practices procuring tissue products must ensure their vendors adhere to strict donor eligibility screening, current good tissue practice (cGTP), and proper product registration guidelines. Understanding these standards mitigates liability while ensuring patient safety across clinical regenerative medicine programs.

Understanding FDA 21 CFR Part 1271 in Clinical Practice

Title 21, Part 1271 of the Code of Federal Regulations (CFR) was created by the U.S. Food and Drug Administration (FDA) to prevent the introduction, transmission, and spread of communicable diseases through human cells, tissues, and cellular and tissue-based products. For practice administrators and clinicians integrating human tissue allografts into their clinical offerings, compliance with Part 1271 is a prerequisite for risk management and operational sustainability.

HCT/Ps include structural tissues such as amniotic membrane, umbilical cord tissue, skin allografts, and bone matrix, as well as non-structural cellular preparations. Under FDA regulations, tissue products are categorized primarily into two tiers:

Section 361 HCT/Ps: Products regulated solely under Section 361 of the Public Health Service (PHS) Act. These products do not require pre-market approval if they meet specific criteria: minimal manipulation, intended for homologous use, not combined with other active agents, and producing systemic effects only under strict exceptions.
Section 362/FD&C Act Products: Products that do not meet all criteria for Section 361 are regulated as biologics, drugs, or medical devices, requiring an Investigational New Drug (IND) application or pre-market approval (BLA/510k) prior to commercial distribution.

Procuring compliant biologics requires medical practice leaders to rigorously verify that every tissue allograft supplied for clinical use satisfies these legal classifications.

Core Regulatory Pillars of 21 CFR Part 1271

To construct a bulletproof procurement workflow, practice managers must understand the four primary subparts of Part 1271 that apply to tissue processors, tissue banks, and distributors.

Subpart A: Scope and Definitions

Subpart A outlines which products fall under HCT/P regulations and sets definitions for minimal manipulation and homologous use. Minimal manipulation for structural tissue means processing that does not alter the original relevant characteristics of the tissue relating to its utility for reconstruction, repair, or replacement.

Subpart B: Registration and Listing

Any facility that manufactures, processes, packages, stores, or distributes HCT/Ps must register annually with the FDA using Form FDA 3356. Practice managers must verify that every vendor supplying tissue allografts maintains an active, updated FDA establishment registration.

Subpart C: Donor Eligibility

Subpart C sets strict requirements for donor screening and testing. Human donor tissue must be screened for relevant communicable disease agents and diseases, including HIV, Hepatitis B, Hepatitis C, Treponema pallidum (syphilis), and human T-lymphotropic virus (HTLV) where applicable. Testing must be performed by a CLIA-certified laboratory using FDA-cleared donor screening tests.

Subpart D: Current Good Tissue Practice (cGTP)

cGTP governs the methods used in, and the facilities and controls used for, the manufacture of HCT/Ps. This includes environmental monitoring, equipment sterilization, environmental control, processing validation, and robust recordkeeping.

Vendor Procurement Checklist for Practice Managers

Practice managers bear the operational responsibility of procuring compliant tissue products while maintaining strict inventory controls. When auditing a potential tissue vendor or distributor, use this verification checklist before onboarding any product line:

FDA Registration Verification: Obtain the vendor's and manufacturer's FDA Form 3356 establishment registration number. Verify its current status on the official FDA Tissue Establishment Registration database.
Certificate of Analysis (CoA) & Certificate of Conformance (CoC): Ensure every individual tissue lot is accompanied by a CoA confirming negative results for all mandatory communicable disease panels.
Traceability Documentation: Verify that the tissue unit contains clear, standardized identifiers (such as a unique donor ID and lot code) that link the patient record directly to the manufacturer source.
Cold Chain & Storage Validation: Review temperature logging protocols during shipping and storage. Confirm that your practice possesses compliant refrigeration or cryo-storage equipment matching manufacturer specifications.
Adverse Event Reporting Protocol: Confirm that the vendor has a documented procedure for handling product complaints, tracking adverse reactions, and notifying the FDA when mandatory criteria are met.
Staff Credentialing and SOPs: Maintain written Standard Operating Procedures (SOPs) detailing tissue receipt, inspection, logging, storage, and disposal of compromised or expired inventory.

Evaluating these criteria protects your facility against supply chain interruptions and regulatory non-compliance. Administrators managing multi-specialty practices can learn more about tailored operational frameworks through our resource guide for regenerative medicine doctors.

Clinical Governance: Homologous Use and Minimal Manipulation

While practice managers oversee procurement workflows, treating physicians and medical directors hold clinical responsibility for how tissue allografts are used in patient care.

Under FDA guidelines, homologous use means the repair, reconstruction, replacement, or supplementation of a recipient's cells or tissues with an HCT/P that performs the same basic function in the recipient as in the donor. For instance, using structural matrix tissue for dermal defect repair or tendon sheath reinforcement fits homologous definitions, provided processing has not altered the native tissue architecture.

Clinicians must refrain from promoting or utilizing 361 HCT/Ps for non-homologous indications or making unapproved disease-treatment claims. Doing so shifts the product's regulatory status from a 361 tissue allograft to an unapproved biological drug, creating regulatory liability for the treating practice.

Reviewing updated clinical literature and regulatory guidance on publications helps physicians maintain clinical protocols aligned with federal guidelines.

What This Means for Your Practice: Action Plan

Achieving full alignment with FDA 21 CFR Part 1271 requires a proactive compliance structure across both administrative and clinical workflows. Practices should take the following immediate steps:

Audit Current Tissue Suppliers: Request current FDA registration documents, processing protocols, and sample CoAs for every tissue product in your inventory.
Establish a 10-Year Record Retention System: FDA regulations require that tissue tracking records—connecting donor lot numbers to specific patient charts—be retained for a minimum of 10 years after receipt or expiration.
Standardize Internal SOPs: Create clear written instructions for receiving incoming shipments, inspecting packaging integrity, verifying temperature logs, and recording tracking data prior to clinical application.
Train Procurement and Clinical Staff: Conduct annual compliance training for medical assistants, practice managers, and clinicians on tissue handling, safety protocols, and proper documentation.

Building a Compliant Supply Chain

Navigating federal biologics compliance does not have to burden your practice's operational efficiency. Working with an experienced medical device and tissue distributor provides access to rigorously vetted products, transparent lot documentation, and ongoing support.

To review compliant biological allografts, advanced delivery systems, or regulatory documentation for your practice, visit our team at contact to schedule an operational consultation.